A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effects of Bifidobacterium longum (BL) NCC3001 on Intestinal and Psychological Symptoms in Subjects with Irritable Bowel Syndrome (IBS)

Start DateJanuary 2022
End DateMarch 2023
Trial Duration10 weeks
Number of Visits4 visits + 1 phone call
Lead CRCAlexus McCue
StatusCurrently recruiting
Phone705-566-0005